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Introduction 
Breast cancer (hereinafter - BC) is the most frequent type of cancer among women in the 
Republic of Kazakhstan, accounting for almost 12% of all cases of cancers in the country [1]. 
Kazakhstan has the highest rates of breast cancer in the Central Asian region.  Local physicians 
associate it with lack of breastfeeding, use of hormonal drugs, and poor ecological conditions 
[2]. There were 3,400 new cases of BC in Kazakhstan in 2016 [3], while number of deaths in the 
same year reached 1,022 [4]. The age-adjusted death rate from BC is 21.50 per 100,000, which 
ranks Kazakhstan 35th in the world [32]. The prevalence of BC reached 22.7 per 100,000 in 
2013, and it has been increasing constantly, affecting younger population aged 25-40. It also 
takes the first place in mortality rates among all cancers in the 45-50-year age group. Between 
1990 and 2010 the annual years of healthy life lost from breast cancer in Kazakhstan has 
increased by 44.0% [5]. In 1990, BC led to 38,000 years of life lost (hereinafter - YLL) in 
Kazakhstan. In 2010, the prevalence rate of BC has raised by 17% leading to 44,000 YLL [6].   
 
Early detection of BC is an effective public health measurement taken to decrease both the 
prevalence and the incidence of BC. There are three methods of detection of BC. The first is self-
examination, which is more applicable in resource-limited settings. The second is the clinical 
examination of women with symptoms and signs. The third is the mammography-screening 
program (hereinafter - MSP), which is the systematic application of a screening examination in a 
presumably asymptomatic population. In Kazakhstan, mammography is offered to women aged 
50-60 without symptoms of breast cancer and it is free of charge. Its purpose is to identify 
women with mammary gland abnormalities suggestive of cancer. Until 2008, clinical 
examination of symptomatic population was the predominant approach. 
In Kazakhstan, free, population-based MSP was introduced in 2008 [7]. It is biannual and it 
targets women aged 50, 52, 54, 56, 58, and 60. In 2011, the whole program underwent a quality 
improvement in compliance with the European guidelines for quality assurance. 
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The MSP includes mammography screening with reading of the mammogram by two 
radiologists. The first reading is conducted in the local hospital where the woman underwent the 
mammography. Further, the screening is sent to the Kazakh Institute of Oncology and Radiology 
(hereinafter - KIOR) in Almaty for the second reading. During 2016, the MSP covered 389 352 
women and detected 830 new cases of breast cancer, what amounted to 0.2% of the total number 
of screened women. [8]. According to the international recommendations, the detection rate of 
BC by mammography needs to be about 0.2% from the coverage rate [11].     
                                                              
Even though mortality rates from BC are decreasing since the introduction of the MSP in 2008, 
the incidence rates increased between 2006 and 2013. This continuous incidence growth might 
be explained by improved diagnostic methods and early detection of BC among the 
asymptomatic population.  
According to the KIOR, in the long run, the MSP should reduce the breast cancer mortality rate 
by 25% [9]. Treatment costs of women diagnosed with BC in Kazakhstan varies significantly 
depending on the development of the disease in both public and private sector [10]. 
 
The MSP has proven to be effective in many developed countries [11]. Moreover, there is 
evidence a nation-wide MSP can decrease breast cancer mortality by almost 20% in the screened 
against the unscreened group [12]. In the United States, the MSP helped to decrease breast 
cancer mortality by 40% since 1990 [12]. 
Japanese researches has demonstrated that mammography provides the most cost-effective 
diagnostic approach in comparison with other methods of BC detection [13]. MSP is feasible and 
effective in countries with proper health infrastructure that can afford long-term organized 
population-based screening programs [14]. Nevertheless, low-cost screening methods, such as 
clinical breast examination and self-examination, could be applied in resource-limited settings. 
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According to the Ministry of Health, decline of BC mortality rates in Kazakhstan is attributed to 
its early detection by screening [15]. In high-income countries, almost 80% of screened women 
with BC are diagnosed at stage I, thus, screening leads to higher survival rates compared to 
women with advanced stages of BC. As a result, BC mortality rates in high-income countries 
decreased by 30% after 5-7 years of screening. It is projected that further implementation of the 
nation-wide mammography-screening program in Kazakhstan will obtain additional health 
benefits in BC outcomes for a low cost. 
 
Objective 
The objective of this study is to estimate health and financial outcomes associated with the 
nation-wide mammography-screening program in Kazakhstan.  
 
Methods 
Perspective 
A cost-benefit analysis (hereinafter - CBA) was conducted to assess the economics feasibility of 
the MSP in the Republic of Kazakhstan. The analysis was implemented from the perspective of 
both screened women and the Ministry of Health (hereinafter - MoH). The MoH was selected as 
it funds and controls the national screening program. At the same time, the MSP affects women’s 
personal quality of life and its expectancy by early diagnosis and prevention of the development 
of BC to advanced stages. The introduction of a social health insurance in Kazakhstan 
necessitates that health services be seen not only as a necessity but also as an economic good that 
requires health economics assessments. 
To conduct an exhaustive health economics analysis we used several measurements of health and 
financial outcomes of the MSP. These include life years saved, value of a statistical life, quality-
adjusted life years, financial outcome and incremental cost-effectiveness ratio. 
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A life years (hereinafter - LYs) saved estimate was calculated, since it shows how many 
additional LYs the MSP saved among screened women compared to the unscreened cohort.  
To estimate economic outcomes of the MSP, cost-utility analysis was applied. It uses quality-
adjusted life years (hereinafter - QALYs), which is a gain in life expectancy adjusted for its 
quality. This supports a patient-centered decision-making to judge the benefits of the 
mammography screening while taking into consideration its financial and non-financial burden.  
Measurement often used in cost-benefit analysis is a value of statistical life (hereinafter - VSL), 
which represents the marginal rate of substitution between income and mortality risk. The VSL 
estimate has been selected as it shows the societal impact of the MSP. 
Another financial outcome applied in this research is financial savings for treatment of BC. In 
other words, we assessed how much money the MSP saved due to the difference in stage 
distribution among screened and unscreened women with BC. 
Finally, using such indicators as cost of screening, cost of treatment, and the number of QALYs 
gained per each group, we were able to calculate the incremental cost-effectiveness ratio 
(hereinafter - ICER) to estimate the amount of money spent per one QALY.  
CBA was chosen for our economic analysis since it allows costs to be justified not only in terms 
of health effects but also in monetary benefits, thus, allowing us to see the effectiveness of the 
use of an allocated budget.  
Based on the availability of the data, the analysis and calculations consider the MSP in a year 
2016. 
 
 
 
Comparison Group 
According to current literature, the comparison group in our analysis comprises those women, 
who were not screened, as there is no other traditional method of breast cancer screening. 
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However, some research compare effectiveness of mammography screening with other 
diagnostic tools, such as MRI or ultrasound [16]. 
 
Discounting  
We developed a model where we are follow a screened woman, in theory, 11 years, between the 
time they are 50 and 60. We use a uniform distribution to calculate constant probabilities of 
treatment.  Furthermore, we have each "screened" woman screened 6 times over the 11-year 
period. Relevant cost data were provided by the Center of Oncology and Radiology in Astana 
[35]. To conduct a more accurate representation of financial outcomes, a discount rate of 4.8% 
per annum was applied for all costs. Such discount rate was used as average inflation in 
Kazakhstan is equal to 4.8% [40].  All costs were converted to USD, the dollar to tenge 
exchange rate for the June 30, 2016 was utilized at USD 1= 339 KZ tenge. 
 
5-year survival analysis  
A key assumption about mammography is that it detects a higher proportion of breast cancers at 
earlier stages that would have otherwise developed to advanced stages. 
First of all, to make adequate comparison, we assume equal number of women in both screened 
(n=830) and unscreened groups. Based on 5-year survival rates and distribution of women with 
different stages of breast cancer we are able to calculate the potential number of lives saved by 
mammography.  Survival rates and distribution of women across cancer stages have been 
obtained from the Center of Oncology in Astana.   
The analysis of a group 5-year survival has been conducted by multiplication of survival rates of 
woman with BC by the proportion of women with a corresponding stage of breast cancer. 
 
 
Life Years Saved 
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Understanding the additional life years given to women by early detection of breast cancer is 
essential as substantial finances are invested to provide mammography to population. Median 
survival rates were applied to estimate the difference of life years saved due to screening versus 
no screening.  
To estimate the amount of life years gained in both screened and unscreened groups, the number 
of median survival rates have been multiplied by the number of women with a corresponding 
stage of breast cancer.  
 
 
Quality-Adjusted Life Years            
Quality adjusted life years (hereinafter - QALYs) is a health outcome measure based on life 
years gained adjusted for quality of life, which is scored between 0 for death and 1 for full 
health. QALYs is an effective measurement, used in health economic analysis, which 
demonstrates the effectiveness of health services and guides future decision-making.                              
To estimate the number of QALYs gained by the MSP among women aged 50-60 with breast 
cancer, it is essential to estimate their life expectancy and adjust it for quality of life and compare 
it with QALYs without screening. 
 
Estimating life expectancy 
According to the WHO, life tables, the additional expected life of women aged 50-54 years in 
Kazakhstan is around 28 years, and the additional expected life of women aged 55-59 is 23.7 
years. Weighted average life expectancy of women aged 50-60 is calculated at 26 years. Such an 
adjustment is necessary for our analysis as it demonstrates that the MSP can save additional life 
years, which significantly changes QALYs.   
 
Life Years gained (LY) is a measure where remaining life expectancy is taken into account as it 
gives more weight to younger population because saving the life of a teenager gains more life 
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years than saving the life of a pensioner. LYs are estimated as the remaining lifespan at the point 
of each averted death. 
In our analysis we have accounted for average time of treatment of breast cancer. Therefore, if a 
woman diagnosed with breast cancer at the age of 50 undergoes treatment until complete 
recovery, it is expected that she would live about 26 additional years. Table 1 shows life 
expectancy of the MSP target group.    
 
Table 1. Life expectancy of the MSP target group according to the WHO life tables. 
Age group Life expectancy Population [37] Average life expectancy 
(weighted for population) 
50-54 28 285,592 14,6 
55-59 23,7 261,366 11,4 
Total   26 
 
 
Estimating quality of life 
Quality of life (hereinafter - QoL) is usually measured by five dimensions: self-care, discomfort 
and pain, mobility, usual activities, anxiety and depression, which is scored between “0” for 
death and “1” for full health. Because of illnesses related to aging, the normal quality-of-life 
coefficient of women aged 50-60 years is assumed to be 76%. [19] Table 2 shows QoL 
coefficients for different stages of BC. Quality-of-life of women with stage I of BC is assumed to 
be 90% of the estimates for a normal quality-of-life. Quality-of-life for stage II of breast cancer 
is 75% of the normal state, while it is less than 60% for women with stage III-IV BC and distant 
metastasis. [19] 
The decrease of quality of life is assumed to take place only during treatment and, in some cases, 
during reoccurrence of breast cancer. In other words, after successful treatment, which depends 
on the development of BC, a woman continues to live a normal life.  
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To assess the quality of life of women after remission, the natural decrease of the QoL index 
needs to be taken into account. Thereby, QoL coefficient of healthy women aged 50-60 is about 
76% of a QoL of a healthy women aged 25-30. Whereas for women aged 61-70, QoL coefficient 
is equal to 74%, and for women aged 71-80 it is 70%. [20] 
 
Table 2. Quality of life coefficients and its reduction due to BC 
 
Estimating QALYs 
To estimate the number of QALYs, we assumed equal distribution of women across age groups 
dividing 830 cancer cases by 6 age groups: 50, 52, 54, 56, 58, 60. 
To analyze the number of QALYs gained among screened and unscreened women, their life 
expectancies has been multiplied by the quality of life coefficient, which corresponds to certain 
stage of BC. 
 
 
Incremental Cost-Effectiveness Ratio 
The Incremental Cost-Effectiveness Ratio (ICER) has been applied as a measure used in benefit-
cost and cost-utility analysis of a health care interventions. The ICER is defined by dividing the 
difference between costs of two interventions by the difference in their health outcomes (QALYs 
gained).  
The ICER represents the average cost associated with one extra unit of the measure of effect 
(USD per QALY).  
The Incremental Cost-Effectiveness Ratio can be estimated as: 
                     ICER =
𝐶𝑂𝑆𝑇 ൫𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔൯− 𝐶𝑂𝑆𝑇 (𝑛𝑜 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔)
𝑄𝐴𝐿𝑌 (൫𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔൯−𝑄𝐴𝐿𝑌൫𝑛𝑜 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔൯
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Where C1 and E1 are cost and effect in the intervention group (screened) and where C0 and E0 
are cost and effect in the control group (non-screened). 
 
Value of a Statistical Life  
The value of a statistical life (VSL) is the marginal rate of substitution between income and 
mortality risk. The VSL indicates how much an individual is willing to pay to reduce the risk of 
death.  The VSL is used in CBA to assess the efficiency of health policies intended to reduce 
risk. The term “statistical” refers to changes in the risk of death.  
The VSL represents the amount of money a person views as equivalent to a change in his own 
mortality risk, for example, in deciding whether to spend money on protective equipment or 
safer products.  
Value per statistical life year (VSLY) is estimated by dividing VSL by the average (discounted) 
remaining life expectancy. VSLY is the rate at which an individual substitutes money for gains 
in life expectancy. To determine the value per statistical case, VSLY is multiplied by the 
(discounted) expected years of life extension for all people affected by the policy. Therefore, to 
estimate the total value of life saved by mammography, we multiply the VSLY by the number of 
QALYs saved. 
 
Cost Savings per Treatment 
On average, mammography per one woman in Kazakhstan costs the government 14 USD [33].  . 
The total cost of the MSP includes the expenses for equipment, technical support, staff 
education, software, infrastructure and salaries. In total, the annual cost of the program in 2016 
was 5,450,928 USD, which resulted from screening of 389,352 women aged 50, 52, 54, 56, 58, 
and 60.  
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In Kazakhstan, costs associated with treatment of breast cancer vary depending on tumor 
development. The average price per consultation for a clinical examination is about 9 USD. One 
course of chemotherapy costs about 500 USD, while women with advanced stages of BC need at 
least four such courses. Cost of surgery varies from 700 to 1,500 USD. The most expensive is 
radiation therapy, which costs about 30,000 USD per woman. Radiation is necessary for patients 
with advanced stages of BC. In addition, if a woman develops stages III or IV, targeted drugs are 
included into therapy. Thereby, cost of treatment for a woman with stage I BC is about 5,000 
USD, treatment of a patients with stage II BC costs around 30,000 USD, while costs of treatment 
of women with stage III and IV costs from 36,000 USD to 40,000 USD, respectively [1;10;35]. 
 
By identifying breast cancer on earlier stages, screening may lead to timely therapy and large 
savings. Knowing the cost of treatment and the difference in stage distribution between screened 
and unscreened groups, we are able to estimate the total cost of treatment per each cohort. In 
other words, the number of cases has been multiplied by the averaged and discounted cost of 
treatment of the corresponding stage of BC. 
 
Sensitivity analysis  
We conducted 25 different one-way sensitivity analyses. First one is a sensitivity analysis based 
on the coverage rate observed under the MSP. For this purpose, we used 30%, 50%, 71%, 90% 
and 100% coverage rates to assess how such diverse screening scenarios can affect our 
outcomes. Performing second sensitivity analysis, we assessed how different values of a 
statistical life can change the benefits of mammography. We used such values of VSL as 
500,000, 1,000 000, 1,200 000, and 2,000 000 USD.  We also conducted sensitivity analysis 
based on the stage distribution and then assessed the impact of different discount rates on 
financial outcomes. Therefore, this sensitivity analyses consider scenarios where benefits of 
screening are much smaller than what was shown in our base case. In addition, we used one-way 
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deterministic sensitivity analyses varying the average cost of treatment from 10,000 to 30,000 
USD. 
 
Results 
Health outcomes and stage distribution 
During 2016, the MSP detected 830 BC cases: 60% diagnosed as stage I; 25% as stage II; 15% 
as stage III; and 5% as stage IV. The distribution of BC cases among unscreened women showed 
that around 30% of them developed stage I; 30% stage II; 25% stage III; and 15% stage IV. 
Table 3 includes survival rates and stage distribution observed among screened and unscreened 
population. 
 
5-year survival analysis 
Table 3 demonstrates proportions of lives saved among screened and unscreened population.  
We estimated the proportions of lives saved for screened and unscreened population. The table 
demonstrates that 5-year survival rates for the screened group is about 80%, while it is 65% for 
the unscreened cohort. Therefore, we can say that 5 years after diagnosis, 80% of women in the 
screened cohort will survive, whereas only 65% of women will live more than 5 years in the 
unscreened cohort.  
 
Table 3. Proportion of lives saved 
Stage 5-year 
survival 
Distribution 
Screened 
Distribution 
Unscreened 
Cohort 5-year survival Difference 
Screening No 
screening 
Stage I 95% 60% 30% 0.57 0.285  
Stage II 70% 25% 30% 0.175 0.21 
Stage III 50% 10% 25% 0.05 0.125 
Stage IV 22% 5% 15% 0.011 0.033 
Total    0.806 0.653 0.153 
Note: Based on 5-year survival rates and stage distribution of BC diseased women in both 
cohorts we estimated overall difference in survival rates between two groups. 
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Life Years Saved 
Tables 4 and 5 are based on median survival rates and BC stage distribution in both groups. The 
analysis showed that treatment of screened women saved 6,437 LYs. Whereas treatment without 
mammography saved 5,271 LYs. Hence, in 2016, the MSP gained 1,166 life years more than the 
breast clinical examination. Therefore, to increase the number of life years gained due to 
mammography, its coverage rate should be considered among our most central public health 
concerns. 
 
Table 4. Median survival rates and LY saved by the MSP in each stage in the screened cohort. 
Stage of BC Median Survival (years) Number of women LY saved 
Stage I 9 498 4,482 
Stage II 7 208 1,456 
Stage III 5 83 415 
Stage IV 2 42 84 
Total   6,437 
 
Table 5. Median survival rates and LY saved by the MSP in each stage in the unscreened cohort. 
Stage of BC Median Survival (years) Number of women LY saved 
Stage I 9 249 2,241 
Stage II 7 249 1,743 
Stage III 5 208 1,038 
Stage IV 2 125 249 
Total   5,271 
 
Quality-Adjusted Life Years 
To estimate the number of QALYs gained per woman, her quality of life has been multiplied by 
her life expectancy. In other words, a woman with stage I BC aged 50 has quality of life 0.75 and 
28 years of life expectancy, which yields 21 QALYs. However, the number of women aged 50 
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with first stage of BC is 83, which means that the number of saved QALYs for this cohort is 
1746 (21*83). Tables 6-11 present estimations of QALYs saved in the screened cohort.  
The total number of QALYs among unscreened cohort has been estimated by calculating average 
quality of life in each stage of BC, multiplied by 26, which is the average life expectancy of 
women at the age 50-60. (Table 13) 
Total number of QALYs gained due to screening in 2016 was 14,250 (Table 12). However, 
without screening, BC treatment led to savings of 13,432 QALYs. Thus, in 2016 screening saved 
additionally 818 QALYs. 
 
Table 6. QALYs estimates for screened women with BC aged 50 
Stage of BC Stage I Stage II Stage III Stage IV Total 
QoL 0.75 0.7 0.65 0.59  
QALYs 23 20 18,3 16,6  
Number of cases 83 35 14 7  
QALYs per cohort 1,746 677 256 116 2,795 
 
Table 7. QALYs estimates for screened women with BC aged 52 
Stage of BC Stage I Stage II Stage III Stage IV Total 
QoL 0.70 0.64 0.60 0.54  
QALYs 19.5 18 16,7 15,0  
Number of cases 83 35 14 7  
QALYs per cohort 1,620 631 234 105 2,590 
 
Table 8. QALYs estimates for screened women with BC aged 54 
Stage of BC Stage I Stage II Stage III Stage IV Total 
QoL 0.64 0.59 0.54 0.48  
QALYs 18 17 15,2 13,5  
Number of cases 83 35 14 7  
QALYs per cohort 1,493 578 213 95 2,378 
 
Table 9. QALYs estimates for screened women with BC aged 56 
Stage of BC Stage I Stage II Stage III Stage IV Total 
QoL 0.74 0.66 0.60 0.51  
QALYs 17.5 14.2 14.2 12.2  
Number of cases 83 35 14 7  
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QALYs per cohort 1,454 551 199 85 2,289 
 
Table 10. QALYs estimates for screened women with BC aged 58 
Stage of BC Stage I Stage II Stage III Stage IV Total 
QoL 0.68 0.6 0.54 0.45  
QALYs 16 14.2 12.7 10.7  
Number of cases 83 35 14 7  
QALYs per cohort 1,330 499 178 75 2,081 
 
Table 11. QALYs estimates for screened women with BC aged 60 
Stage of BC Stage I Stage II Stage III Stage IV Total 
QoL 0.75 0.7 0.65 0.59  
QALYs 23 20 18,3 16,6  
Number of cases 83 35 14 7  
QALYs per cohort 1,746 677 256 116 2,116 
 
Table 12. Total number of QALYs saved by the MSP in the screened cohort with BC 
Age 50 52 54 56 58 60 Total 
QALYs 
gained 
2,795 2,590 2,378 2,289 2,081 2,116 14,250 
 
Table 13. QALYs for not-screened cohort 
Stage of BC QoL QALYs/woman QALYs/cohort 
Stage I 0.7 18 4,505 
Stage II 0.64 17 4,146 
Stage III 0.58 15 3,143 
Stage IV 0.51 13 1,637 
Total   13,432 
 
Value of a Statistical Life Year  
VSL in Kazakhstan was estimated by the next formula: 
VSL target = VSL base * (Income target / Income base) elasticity  
 
We used VSL and income in Russia as base. Average VSL in Russia is equal to 1.6 million 
USD. [21] Average monthly income in Kazakhstan in 2016 amounted to 450 USD, while in 
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Russia it was around 600 USD. [38, 39] Elasticity equal to “1” was used, since changes in 
income leads to proportionate changes in VSL.  
 Therefore: VSL kz=VSL rs*(Income kz/Income rs)   
                   VSL kz=1,600 000*(450/600) = 1,200 000 USD 
The VSL is usually estimated at the average age, which is 29.3 years for Kazakhstan. [22]. 
At the same time, the total life expectancy of women aged 50-60 is about 76 years, thus, 46 years 
after the average age. With a 4.8% social discount rate over 46 years, the average VSLY in 
Kazakhstan is estimated to be 65,018 USD. 
To assess the savings due to the MSP in terms of VSL, we multiply the VSLY estimate by the 
number of QALYs saved: 65,018 *818 QALYs = 53,184,724 USD. 
Thus, with an additional budget of 2,708,953 USD in 2016, mammography saved the value of 
life estimated for 53,184,724 US dollars.  
 
Table 14. Value of Statistical Life  
VSL in Kazakhstan  $ 1,200,000  
VSLY in Kazakhstan  $ 65,018  
VSL saved by the MSP $ 53,184,724  
 
Cost Savings for Treatment 
Tables 15-20 presents the evaluation of total treatment costs for screened and unscreened 
cohorts, based on the costs of treatment per stage and the stage distribution of BC cases detected 
by screening in 2016. To estimate the average cost of treatment per screened and unscreened 
women we developed a model based on the natural history of breast cancer (tables 16-18). 
Therefore, since unscreened women do not know about their disease, they are likely to develop 
advanced BC stages over a 11-year period, from 50 to 60 years of age.  
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The average cost of treatment of screened women has been also estimated based on cost of 
treatment per woman and stage distribution (Table 15). All costs have been discounted with 
4.8% rate for 11 years (50-60 years).  
Table 19 shows that in 2016 the average discounted cost of treatment per screened woman with 
BC was 12,917 USD, while table 20 shows the average discounted cost of treatment for an 
unscreened woman with BC 16,221 USD.  
To estimate the total cost of treatment per cohort we multiply these numbers by 830. Therefore, 
total cost of treatment per screened cohort was 10,721,883 USD, while for unscreened group it 
was estimated to be around 13,463,857 USD, what means that mammography screening saved 
2,708,953 USD.     
Table 15. Costs of treatment and stage distribution of screened cohort in the Republic of 
Kazakhstan. 
 
Stage of BC Cost of treatment (USD) Number of women 
Stage I 5,000 498 
Stage II 30,000 208 
Stage III 36,000 83 
Stage IV 40,000 42 
Note: As screened women are aware of their disease, they undergo timely treatment, thus, 
preventing BC move to more advanced stages. 
 
 
Tables 16-18. Costs of treatment and stage distribution of unscreened cohort in the Republic of 
Kazakhstan. 
 
Table 16. Year 1 to 3 treatment 
 
Stage of BC Cost of treatment (USD)  Number of women 
Stage I 5,000 498 
Stage II 30,000 208 
Stage III 36,000 83 
Stage IV 40,000 42 
Average cost 16,123 
 
Table 17. Year 4 to 7 treatment 
Stage of BC Cost of treatment (USD)  Number of women 
Stage I 5,000 374 
Stage II 30,000 249 
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Stage III 36,000 125 
Stage IV 40,000 83 
Average cost 20,650  
 
Table 18. Year 8 to 10 treatment 
Stage of BC Cost of treatment (USD)  Number of women 
Stage I 5,000 249 
Stage II 30,000 249 
Stage III 36,000 208 
Stage IV 40,000 125 
Average cost 25,500 
Note: As unscreened women do not know about the progression of BC, the development of the 
disease continues over the whole period of time (50-60 years), thus, moving from early to 
advanced stages making treatment more expensive every year. 
 
 
 
Table 19. The discounted average cost of treatment for screened group with BC 
Age 50 52 54 56 58 60 
Average cost of treatment (USD) 16,123 16,123 16,123 16,123 16,123 16,123 
Present value of treatment (USD)* 16,123 14,679 13,365 12,169 11,080 10,088 
*4.8% discount rate was applied 
Average cost of treatment per screened woman also includes the cost of screening per one 
woman 
 
Table 20. The discounted average cost of treatment for unscreened group with BC 
Age 50 51 52 53 54 55 56 57 58 59 60 
Average 
cost of 
treatment 
(USD) 
16,123 16,123 16,123 20,650 20,650 20,650 20,650 20,650 25,500 25,500 25,500 
Present 
value of 
treatment 
(USD)* 
16,123 15,384 14,679 17,940 17,118 16,334  15,586 14,872 17,524 16,772 15,956 
*4.8% discount rate was applied 
Average cost of treatment per unscreened woman also includes the cost of consultation and 
clinical examination 
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Incremental Cost-Effectiveness Ratio 
We already estimated that mammography additionally saved 818 QALYs, but to assess ICER we 
also need to estimate the difference between costs per screened and unscreened women who had 
breast cancer.  
To assess the cost of the MSP we incorporated the total cost of screening itself and expected cost 
of treatment of 830 diseased women, which amounted to 16,172,811 USD. Total treatment cost 
of screened woman equals USD 10,721,883 and screening cost equals USD 5,450,928.            
Cost of treatment of the unscreened group amounted to 13,463,857 USD (Table 21). Thus, the 
MSP gained 818 QALYs with an additional budget of 2,708 953 USD. Therefore, ICER of the 
MSP in 2016 amounted to 3,311 USD per QALY gained, which is less than the national annual 
GDP per capita in Kazakhstan, which in 2016 was 7,510 USD. According to the WHO policy, 
the ICER less than the national annual GDP per capita is considered highly cost–effective. [23] 
Table 21. ICER of the MSP with 4.8% discount rate (monetary values in USD millions)  
 
 
Discussion 
Screened cohort  
Total costs 16.1 
Screening costs  5.4 
Diagnosis and treatment costs 10.7 
QALYs gained 14,250 
  
Unscreened cohort  
Total Costs 13.4 
Screening costs 0 
Diagnosis and treatment costs 13.4 
QALYs gained 13,432 
  
Difference (Screened – Unscreened)  
Total costs (Million USD) 2.7 
Screening costs 5.4 
Diagnosis and treatment costs -1.6 
QALYs 818 
ICER (USD/QALY) 3,311 
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Mammography screening has proven to be effective in many developed countries. However, the 
cost-effectiveness of screening programs in developing countries such as Kazakhstan has not 
been widely studied. To our knowledge, this is the first published health economics analysis of 
thebreast cancer screening program in Kazakhstan, which began in 2008.  
It is known that in countries with established screening programs more cases of breast cancer are 
diagnosed at earlier stages compared to countries that did not introduce population-based 
screening.  
 
Mammography has proven to decrease breast cancer mortality, with a population-based 
sensitivity of up to 80% and specificity 83% (mammograph “Mammonat 3000 NOVA”). One of 
the indicators of effectiveness of screening is a constant decrease of rates of BC cases at 
advanced stages (III-IV). In Kazakhstan, mammography led to a shift in the stage distribution of 
breast cancers in a way that a smaller quantity of cases were diagnosed at stages III and IV. 
Concurrently, there has been a major increase in the number of breast cancers at Stage I.  
We conducted an extensive sensitivity analysis and found that for the majority of scenarios the 
ICER would stay below the cost-effectiveness threshold. 
 
LYs saved is a relatively simple and transparent measurement of population health. Our analysis 
shows that mammography saved 1,229 life years. However, the estimate LY saved is often 
criticized as it ignores changes in health state in comparison with QALYs. Our research shows 
that in 2016, mammography additionally saved 818 QALYs when compared to no screening 
scenario. However, the QALY measurement itself cannot be judged upon about the effectiveness 
of health programs, for this purpose incremental cost-effectiveness ratios are used. Analysis of 
ICER showed that the MSP in Kazakhstan is very cost effective.  
 
Main objective of this research was not only to assess health outcomes associated with screening, 
but, also to evaluate the economic aspects and financial justification of using this early detection 
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method in resource-constricted settings.  Financial outcomes that we used are ICER, VSL and 
cost savings for treatment. The study showed that despite the high cost of the program, 
mammography leads to substantial savings due to prevention of developing advanced stages, 
thus, cheaper treatment.  We used the value of a statistical life to assess the social impact of 
screening. The VSL estimate showed that the MSP might lead to substantial social savings. 
The consequences of late diagnosis of BC are lower survival, higher morbidity, and higher costs 
of care, resulting in disability and avoidable deaths. Early mammography screening is a vital 
public health strategy in all settings since it improves outcomes by detecting cancer at the earliest 
stages.  
Because of assumptions and uncertainties in our study we performed an extensive sensitivity 
analysis, which showed that mammography screening in Kazakhstan is cost effective in the 
majority of scenarios remaining below the triple GDP per capita threshold. After the program 
was launched in Kazakhstan, breast cancer mortality rates among screened women has 
constantly decrease.  In the USA mammography led to 23% decline of mortality rates from 
breast cancer, while in Sweden such rates dropped by 31% [24]. Such decrease in mortality may 
also be expected in Kazakhstan under higher screening rates. 
 
Strengths 
To our knowledge, this is the first published research on the effectiveness of the mammography 
program in the Republic of Kazakhstan. We used non-monetary and monetary measurements to 
provide a comprehensive and pervasive picture of the effectiveness of the program to patients, 
physicians and policy-makers. 
The study includes both cost-effectiveness and benefit-cost analysis to assess health outcomes 
and financial aspects of the screening program using five measurements: LYs, QALYs, ICER, 
VSL and cost savings for treatment. 
24 
 
 
Another strong side of this paper is that QALYs were adjusted for both, time of treatment of 
different BC stages and natural decrease of quality of life over time. Also, detailed data of 5-year 
survival and stage distribution allowed us to estimate health and financial outcomes more 
precisely and proved that a nationwide biennial mammography screening policy between ages 
50-60 is highly cost-effective.  
 
Limitations 
Our analysis has some limitations that should be considered.  We have chosen to analyze 
screening from the perspective of the Ministry of Health, which is why our research does not 
take into account personal cost of breast cancer, such as salary loss, costs of transportation from 
rural areas, costs of medicine, etc. In addition, screening itself may cause non-monetary harms 
like overdiagnosis or false-positive results what may lead to unnecessary treatment and radiation. 
Estimating such harms would contribute to the comprehensive analysis of breast cancer 
screening program. Secondly, with such limited data available, we assumed equal distribution of 
BC cases among age groups. Another assumption that had to be made because of scarce data is 
that probabilities of each cancerous stage is independent of age. Lastly, we did not conduct 
standardized survey about the quality of life of women with BC, rather obtained them from the 
literature review. 
 
Literature Review 
Such databases as Medline, PubMed, Cochrane Library, and Up-to-date were utilized using 
PICO method (Table 22) to find papers with health and financial outcomes relevant to the breast 
cancer screening program. 
Inclusion and exclusion criteria have been applied. Only Research in English has been chosen for 
our review. Economic analyses of other diagnostic tools for BC and studies with young 
population were excluded.  
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Table 22. Search terms 
 
 
In the study called “Effect of screening mammography on breast cancer survival in comparison 
to other detection methods: A retrospective cohort study” [28] authors used Kaplan–Meier 
survival curves for screening mammography, clinical breast examination, and self-detection. 
Figure 2 demonstrates that women who underwent mammography have 5-year survival rate 
equal to 98.3%, while clinical examination and self-detection, survival rates amounted to 94.3%, 
and 84.8%, respectively (Figure 2). 
 
 
 
 
 
 
Figure 2.   
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In the study called “Cost-effectiveness of population-based mammography screening strategies 
by age range and frequency”, [29] R. Patakya, N. Phillipsb, S. Peacocka observed increase of 
annual mortality reduction from 9.7% to 17.0% changing target age from 50-60 to 40-74 year old 
women with ICER of USD 28,921 per QALY relative to no screening. 
  
In “Cost-Effectiveness and Harm-Benefit Analyses of Risk- Based Screening Strategies for 
Breast Cancer” by E. Vilaprinyo, C. Forne, M. Carles, M. Sala. [30], authors stated that  
biennial screening of women aged 50-69 is the  most cost-effective strategy, with an ICER of 
USD 28,921 per QALY, while screening of women aged 70-74 provided little benefit, regardless 
of screening frequency. 
 
Another study that proves mammography screening to be effective is “Cost effectiveness of the 
NHS breast screening program” [31] by Paul D P Pharoah and B. Sewell. 
They followed 364,500 50-year old women for 35 years, comparing them to a similar cohort of 
women who received screening every 3 years between ages 50 and 70 and further follow up for 
15 years.  The screened cohort had 1521 less deaths from breast cancer compared to the 
unscreened women.  Also, screening was associated with 2,040 additional QALYs at cost of 
£42.5 million—and with ICER of £20,800 per QALY gained.  This study represents good value, 
since it has large sample size, long time to follow up and it is implemented on a solid evidence 
base.  
In their book “Radiation Health Risk Sciences” 2009, [36], professors M.Nakashima and 
S.Yamashita emphasized that due to high levels of radiation in Eastern Kazakhstan 
(Semipalatinsk nuclear testing), the incidence of breast cancer in in this area is 1.5 fold higher in 
comparison with the average rate of breast cancer in Kazakhstan, and 2.5 fold higher than BC 
incidence in South Kazakhstan. [28] Such differences in the incidence of BC have to be taken in 
account by policy-makers in the process of developing strategy for the MSP in Kazakhstan.  
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Breast cancer screening programs should always be monitored and constantly evaluated in terms 
of cost-effectiveness, economic impact, and improved health determinants. There is always an 
interplay between potential financial burden and potential health benefits. That is why different 
screening strategies differ in terms of target age, target population, frequency of screenings, and 
others.  
 
Recommendations 
Based on the research findings and international experience, we developed recommendations for 
the MSP strategy for local and foreign policy makers. Despite the success of mammography 
screening, mortality rates from breast cancer in Kazakhstan are still very high with annual 
incidence of BC in Kazakhstan is about 4,000 women [3]. In 2016, 389,352 women were 
screened, and 830 of them were detected to have breast cancer. Based on above, it can be said 
that more than 2,500 women were diagnosed with BC using other means of detection. In other 
words, in 2016 the MSP detected only 20% of new breast cancer cases. Therefore, we may 
increase this proportion using international guidelines, which recommend biannual screening of 
women older than 40 years every two years [24]. However, screening in the age group 40-45 is 
less cost-effective as the incidence of breast cancer in this age group is low. [25] 
The research conducted in Canada showed that the most cost effective strategy for 
mammography is to screen women aged 40-74 biannually [26]. Experience of such countries as 
Switzerland and Sweden shows that biannual screening of women aged 50-69 can increase 
coverage rate to almost 75%. [25]  
In the systematic review of the cost-effectiveness of different breast-screening programs, authors 
reviewed 28 articles from 1993 to 2010. [27] Based on the findings, authors concluded that 
biennial screening for 50-70 aged women is the most recommended and cost-effective strategy.  
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Thus, taking into account the above-mentioned evidence, and experience of developed countries, 
we propose including 45-49 and 60-69 aged women into the target group, thus extending the 
target population to women aged 45-69. Inclusion of wider age range will likely increase the 
number of women coming for mammography and decrease the proportion of detected malignant 
cases. Taking into account differences in BC rates in Kazakhstan we propose to pilot the MSP 
with above-mentioned changes in Eastern Kazakhstan and also include women aged 40-50 in the 
target group. It would lead to decline in the proportion of detected malignant forms since the 
onset of breast tumors in most cases takes place among women in their 40s. Additionally, it 
would lead to large financial savings since more cases would be detected on earlier stages. 
 
 
Conclusion  
Cost effectiveness analyses presented in our paper can contribute to the development of effective 
breast cancer-screening policies to guide the process of adequate distribution of limited resources 
and finances. Taking into account distinguishing economic and demographic characteristics, 
such research can assist governments of developing countries to decide which screening strategy 
to implement. 
 
It can be said that the mere presence of breast screening-program is not enough. Instead, constant 
monitoring, evaluation and control of the implementation should be continuously performed. 
These will help to find a golden standard, a compromise, and a trade-off for fair distribution of 
scarce resources and limited finances on one hand and increase of early-detected breast cancers 
on the other hand.  
Desired outcome measure in our benefit-cost analysis:  number of quality-adjusted life years 
saved (QALYs), life years saved, cost saving per treatment, and value of a statistical life.  
Thus, based on the findings and data provided, referring to the published research articles, and 
based on their results, it can be concluded that the existing breast-screening program is already 
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quite efficient. Moreover, it has to be taken into account that women in Kazakhstan tend not to 
visit their family physician right after the first signs of cancer or any disease due to specific 
population-wide national set of mind.  
Considering reviewed studies, it can be deduced that there are no publications in Kazakhstan 
regarding this important topic. That is why researchers and public health professionals should 
not underestimate the importance of evaluating screening programs in terms of their cost-
effectiveness. This will help to make necessary adjustments and improve further decision-
making determined to increase proportion of early-screened breast cancer cases and help women 
to undergo treatment as early as possible.  
In conclusion, it can be said that more research should be conducted on cost-benefit, cost-
effectiveness, and cost-utility analyses for screening programs in Kazakhstan. Mammography 
screening is a complex public health approach that needs additional resources, infrastructure and 
coordination. Such programs should be implemented only when effectiveness is proved and 
resources are sufficient to justify the effort and costs of screening.  
Finally, when planned efficiently, properly financed and implemented, screening can reduce 
mortality and the risk of developing late stages of breast cancer by 50%. [34] 
 
 
 
 
Sensitivity analysis 
To assess the impact of different variables on health and financial outcomes we conducted 25 
one-way sensitivity analyses. Regardless of the discount rate applied, the organized breast cancer 
screening dominated no screening scenario. Even with the attendance rate equal to 30% the 
ICER is still lower than the GDP per capita threshold. Higher attendance rates in mammography 
resulted in lower ICERs. 
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Changing average cost of treatment did not affect the domination of mammography. As the cost 
of treatment and the number of life years saved rise, the ICER decreases.  
 The greatest impact on ICERs was observed with the rise of the average cost of screening per 
woman. Its increase to 50 USD moves ICER to the triple GDP per capita threshold.  
Changes in the stage distribution of BC cases from earlier to advanced stages also increases 
ICER, decreases the number of life years saved, and even may result in dominance of no 
screening scenario.  Despite variations in coverage rates, the MSP dominated over no screening 
scenario. 
If we restrict the VSL in Kazakhstan to 100,000 USD, we see a decrease in the benefits of the 
MSP. However, such restriction does not lead to financial ineffectiveness of the MSP. 
 
Figure 1. Tornado diagram.  
 
 
The diagram summarizes the results of one-way sensitivity analysis. The x-axis represents the 
ICER per QALY gained by the MSP over no screening. The y-axis represents the parameters 
that were changed and affected the ICERs.  
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Abstract 
Background: We conducted cost-effectiveness and benefit-cost analysis of the organized breast 
cancer-screening program in the Republic of Kazakhstan. The program has been introduced in 
2008, until then, clinical breast examination and self-referral were the only ways of diagnostic of 
breast cancer.  
Objectives: to evaluate health and financial outcomes of the organized mammography-screening 
program comparing with clinical breast examination without screening. 
Methods: a cohort of 830 women, which has been detected to have breast cancer by 
mammography, was compared with 830 women, which has been diagnosed with breast cancer 
by other diagnostic means. Financial and health outcomes have been estimated using such 
measurements as life years saved, quality-adjusted life years, incremental cost-effectiveness 
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ration, and value of statistical life year. Sensitivity analyses were performed to assess 
uncertainty. 
Results: compared to clinical breast examination, an organized mammography yielded 
additional 1,229 life years and 818 quality-adjusted life years. Since the incremental cost-
effectiveness ratio was equal to 3,311 USD per QALY and less than GDP per capita in 
Kazakhstan, breast cancer screening can be considered as highly cost-effective. Moreover, 
mammography led to cost savings associated with treatment. Value of a statistical life estimate 
demonstrated that social savings by mammography were equal to 53,184 724 USD.  
Discussion: The mammography program has proved to be an efficient use of limited resources 
in Kazakhstan. This health-economic analysis showed that the mammography is cost-effective 
and financially beneficial alternative to not using screening. Sensitivity analysis showed that the 
mammography remains cost-effective in a majority of scenarios. 
Keywords: breast cancer, mammography screening, cost-effectiveness analysis, benefit-cost 
analysis. 
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